PhI­II set­back mars Oc­u­lar's glau­co­ma drug/de­vice, though com­pa­ny re­mains 'en­cour­aged' by da­ta break­down

Oc­u­lar Ther­a­peu­tix’s lat­est drug/de­vice — for glau­co­ma — has flopped in its Phase III study, fail­ing the pri­ma­ry end­point to sig­nif­i­cant­ly re­duce in­traoc­u­lar pres­sure ver­sus place­bo. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER